Building a
Better Health
Care System

The biopharmaceutical industry is on the brink of unprecedented breakthroughs, with the potential to revolutionize health care, reduce the burden of disease and create a healthier future for all.

The United States leads the world in the research, development and manufacturing of innovative medicines. But the Inflation Reduction Act’s (IRA) “pill penalty” puts this leadership at risk by discouraging the development of treatments that often come in pill form like a tablet or capsule, also known as small molecule medicines. Under the IRA, these treatments can be price set years before other medicines, signaling to researchers that developing them is not worth the risk.